Securities code: Chongqing Lummy Pharmaceutical Co.Ltd(300006) securities abbreviation: Chongqing Lummy Pharmaceutical Co.Ltd(300006) Announcement No.: 2022014 Chongqing Lummy Pharmaceutical Co.Ltd(300006)
Announcement on submitting to the general meeting of shareholders to authorize the board of directors to approve the guarantee for subsidiaries
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
In accordance with the relevant provisions of the securities law, the company law and the Shenzhen Stock Exchange GEM Listing Rules, the board of directors of Chongqing Lummy Pharmaceutical Co.Ltd(300006) (hereinafter referred to as the “company”) has predicted and analyzed the external guarantee of the company in 2022 according to the overall business plan and capital demand of the company, and plans to submit it to the general meeting of shareholders to authorize the board of directors to approve the guarantee of subsidiaries. The details are as follows:
1、 Overview of guarantee matters
In order to successfully implement the company’s overall business plan for 2022 and meet the company’s capital needs, the company plans to submit to the general meeting of shareholders to authorize the board of directors to approve the authority for the guarantee of subsidiaries. The details are as follows:
1. In the next 12 months, the company will be a holding subsidiary (including a wholly-owned subsidiary) Chongqing Laimei Pharmaceutical Co., Ltd. (hereinafter referred to as “Laimei pharmaceutical”), Hunan Kangyuan Pharmaceutical Co., Ltd. (hereinafter referred to as “Kangyuan pharmaceutical”), Laimei (Hong Kong) Co., Ltd. (hereinafter referred to as “Laimei Hong Kong”), Chongqing Laimei Longyu Pharmaceutical Co., Ltd. (hereinafter referred to as “Laimei Longyu”) Tibet Laimei Deji Pharmaceutical Co., Ltd. (hereinafter referred to as “Laimei Deji”) and Sichuan Yingrui Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Sichuan Yingrui”) provide guarantee for the financing credit, and the cumulative guarantee limit is expected to not exceed 30% of the company’s latest audited total assets, The above guarantees include all guarantees that need to be submitted to the general meeting of shareholders for approval as stipulated in the Listing Rules of gem shares of Shenzhen Stock Exchange and the articles of association.
2. On the premise that the general meeting of shareholders approves the above guarantee matters, the company plans to submit to the general meeting of shareholders to authorize the board of directors of the company to approve the specific matters of providing guarantee to subsidiaries within the above limit, including appropriately adjusting the guarantee object, guarantee amount and financing institution according to the actual financing needs of each holding subsidiary (including wholly-owned subsidiaries). 2、 Basic information of the guaranteed company
(I) Chongqing Laimei Pharmaceutical Co., Ltd
1. Chongqing Laimei Pharmaceutical Co., Ltd
2. Address: 15 / F, Tower B, comprehensive R & D building, No. 2, Yangliu Road, Beibu new area, Chongqing
4. Registered capital: 5 million yuan
5. Business scope: licensed items: drug wholesale; Food sales; Import and export of drugs. (for items that must be approved according to law, business activities can be carried out only after being approved by relevant departments. The specific business items shall be subject to the approval documents or licenses of relevant departments) general items: Sales of personal hygiene products; Sales of special labor protection articles; Sales of sanitary supplies and disposable medical supplies; Information consulting services (excluding licensed information consulting services); Information technology consulting services; Consulting and planning services; Health consulting services (excluding diagnosis and treatment services); Conference and exhibition services; Marketing planning; Brand management; Professional design services; Import and export of goods; Sales of class I medical devices; Purchase and sale of Chinese herbal medicine (excluding Chinese herbal pieces) in the real estate; Acquisition of Chinese herbal medicine; Wholesale of cosmetics; Daily mask (non-medical) sales; Wholesale of protective articles for medical staff; Sales of labor protection articles; Sales of class II medical devices; Sales of agricultural and sideline products. (except for the items that must be approved according to law, the company shall independently carry out business activities according to law with its business license)
6. Main financial data of Laimei pharmaceutical
Unit: Yuan
The total assets of the project from December 31, 2021 / January to December 2021 to December 31, 2020 / January to December 2020 are 1172219049117388235399 short term loans – total current liabilities are 1060916567712362544638 and total liabilities are 106091 , 656.7712362544638 net assets 11130248145025690761 operating income 33823920495436359761 total profit -4602385853 -1586191867 net profit -3912665947 -1389825978 contingencies None none none
(II) Hunan Kangyuan Pharmaceutical Co., Ltd
1. Company name: Hunan Kangyuan Pharmaceutical Co., Ltd
2. Address: No. 8, Kangping Road, Liuyang economic and Technological Development Zone
3. Legal representative: Bai Zhenxiang
4. Registered capital: 65 million yuan
5. Business scope: manufacturing of chemical preparations; Sell the products produced by the company (national laws and regulations)
Except for projects prohibited from operation; Products involving licensed operation can be operated only after obtaining a license); Self operated and
Act as an agent for the import and export of various commodities and technologies, but the state restricts the company to operate or prohibits the import and export of commodities and technologies
except; Drug research and development; Medical consultation; Brand promotion and marketing; Bidding and investment of drugs, sanitary materials and medical devices
Bid agency services; Business information consultation; Marketing planning services; Market management services. Class II medical devices
Production (limited to branches); Wholesale of class II medical devices (items subject to approval according to law shall be approved by relevant departments)
Business activities can only be carried out after approval)
6. Main financial data of Kangyuan pharmaceutical
Unit: Yuan
Total assets of the project from December 31, 2021 / January to December, 2021 to December 31, 2020 / January to December, 20201803236864024264202003 short term loans – total current liabilities 1352738635019892004183 total liabilities 1361413635019999754183 net assets 44182322904264447820 operating income 41223968616916120095 total profit 152331721 – 15896720330 net profit 1, 53784470 – 18543706895 contingencies none none
(III) Laimei (Hong Kong) Co., Ltd
1. Company name: Laimei (Hong Kong) Co., Ltd
2. Registered address: Hong Kong Special Administrative Region
3. Director: Leng Xuefeng
4. Registered capital: USD 100 million
5. Business scope: investment, trade and consulting.
6. Key financial data of lemy Hong Kong
Unit: Yuan
December 31, 2021 / January December 2021 December 31, 2020 / January December 2020
Total assets 1927542733919343880260
Short term borrowings —
Total current liabilities —
Total liabilities —
Net assets 1927542733919343880260
Operating income —
Total profit -68452921 -2230346711
Net profit -68452921 -2230346711
Contingencies none none
(IV) Chongqing Laimei Longyu Pharmaceutical Co., Ltd
1. Company name: Chongqing Laimei Longyu Pharmaceutical Co., Ltd
2. Address: No. 2, Huanan 4th branch road, economic and Technological Development Zone, Changshou District, Chongqing
3. Legal representative: An Lin
4. Registered capital: 100 million yuan
5. Business scope: drug production and sales (items subject to approval according to law shall be approved by relevant departments
To carry out business activities); Sales: chemical raw materials and chemical products (excluding hazardous chemicals); Goods in and out
Export (the above scope is prohibited by laws and regulations and shall not be operated. If the approval is required by laws and regulations, it shall not be obtained
Obtain relevant approval and permission (not allowed to operate)
6. Main financial data of lemy Longyu
Unit: Yuan
The total assets of the project from December 31, 2021 / January to December 2021 / December 31, 2020 / January to December 2020 are 3906405559857780310766 short-term loans-
